{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:02:51Z","timestamp":1774047771275,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012412","name":"Kansai Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.neuropharm.2021.108771","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T10:50:20Z","timestamp":1630320620000},"page":"108771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease"],"prefix":"10.1016","volume":"198","author":[{"given":"Rie","family":"Tohge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1767-9681","authenticated-orcid":false,"given":"Satoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-8468","authenticated-orcid":false,"given":"Norihiro","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-2919","authenticated-orcid":false,"given":"Aya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0439-5682","authenticated-orcid":false,"given":"Masataka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-8101","authenticated-orcid":false,"given":"Hirofumi","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3206-6939","authenticated-orcid":false,"given":"Yusuke","family":"Yakushiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108771_bib1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","article-title":"The 5-HT1A receptor: signaling to behavior","volume":"161","author":"Albert","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.neuropharm.2021.108771_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00091","article-title":"Multifaceted regulations of the serotonin transporter: impact on antidepressant response","volume":"13","author":"Baudry","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108771_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-2236(03)00038-9","article-title":"Presymptomatic compensation in Parkinson's disease is not dopamine-mediated","volume":"26","author":"Bezard","year":"2003","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108771_bib4","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1111\/j.1460-9568.2012.08202.x","article-title":"Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats","volume":"36","author":"Bishop","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108771_bib5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2021.108771_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/mds.26144","article-title":"Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias","volume":"30","author":"Cheshire","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108771_bib7","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Aging and Parkinson's disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2021.108771_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbr.2006.07.004","article-title":"Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease","volume":"174","author":"Field","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2021.108771_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuropharm.2013.08.002","article-title":"Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway","volume":"76","author":"Fukuyama","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108771_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1126\/science.2147780","article-title":"D1 and D2 dopamine receptor regulated gene-expression of striatonigral and striatopallidal neurons","volume":"250","author":"Gerfen","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2021.108771_bib11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2004.07.015","article-title":"Effect of 5-HT1B\/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets","volume":"79","author":"Jackson","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108771_bib12","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1097\/WNR.0b013e3283300fd7","article-title":"Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia","volume":"20","author":"Jaunarajs","year":"2009","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2021.108771_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2018.00030","article-title":"Anatomical inputs from the sensory and value structures to the tail of the rat striatum","volume":"12","author":"Jiang","year":"2018","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.neuropharm.2021.108771_bib14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1126\/science.289.5479.633","article-title":"Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function","volume":"289","author":"Kaneko","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2021.108771_bib15","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0920-1211(99)00010-8","article-title":"Effects of zonisamide on K+ and Ca2+ evoked release of monoamine as well as K+ evoked intracellular Ca2+ mobilization in rat hippocampus","volume":"35","author":"Kawata","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108771_bib16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1440-1681.2006.04491.x","article-title":"Voltage and ionic regulation of human serotonin transporter in xenopus oocytes","volume":"33","author":"Li","year":"2006","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib17","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1528-1167.2007.01093.x","article-title":"The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy","volume":"48","author":"Loscher","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108771_bib18","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1073\/pnas.89.7.3020","article-title":"Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers","volume":"89","author":"Maroteaux","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of Americ"},{"key":"10.1016\/j.neuropharm.2021.108771_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0891988708328219","article-title":"Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease","volume":"22","author":"Montel","year":"2009","journal-title":"J. Geriatr. Psychiatr. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.expneurol.2009.05.033","article-title":"Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model","volume":"219","author":"Munoz","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing- off in Parkinson's disease: a randomized, double- blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108771_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson's disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2021.108771_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nbd.2010.01.012","article-title":"Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease","volume":"38","author":"Navailles","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2021.108771_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00213-010-2029-y","article-title":"Presynaptic control of serotonin on striatal dopamine function","volume":"213","author":"Navailles","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108771_bib25","article-title":"Zonisamide enhances motor effects of levodopa, not of apomorphine, in a rat model of Parkinson's disease","volume":"2018","author":"Nishijima","year":"2018","journal-title":"Parkinson's Dis."},{"key":"10.1016\/j.neuropharm.2021.108771_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-1211(98)00109-0","article-title":"Biphasic effects of zonisamide on serotonergic system in rat hippocampus","volume":"34","author":"Okada","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108771_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108771_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neures.2017.04.003","article-title":"Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats","volume":"122","author":"Oki","year":"2017","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2021.108771_bib29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s12035-019-01739-x","article-title":"Selective regulation of 5-HT1B serotonin receptor expression in the striatum by dopamine depletion and repeated L-DOPA treatment: relationship to L-DOPA-induced dyskinesias","volume":"57","author":"Padovan-Neto","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib30","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/mds.26326","article-title":"Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity","volume":"30","author":"Paolone","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108771_bib51","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.neuropharm.2021.108771_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ana.22231","article-title":"L-3,4-Dihydroxyphenylalanine-Induced sprouting of serotonin axon terminals: a useful biomarker for dyskinesias?","volume":"68","author":"Picconi","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/mds.27261","article-title":"Motor complications in Parkinson's disease: striatal molecular and electrophysiological mechanisms of dyskinesias","volume":"33","author":"Picconi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108771_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1134\/S0006297917030099","article-title":"Neurotrophic factors (BDNF and GDNF) and the serotonergic system of the brain","volume":"82","author":"Popova","year":"2017","journal-title":"Biochemistry-Moscow"},{"key":"10.1016\/j.neuropharm.2021.108771_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ceca.2014.04.003","article-title":"Electrical coupling between the human serotonin transporter and voltage-gated Ca2+ channels","volume":"56","author":"Ruchala","year":"2014","journal-title":"Cell Calcium"},{"key":"10.1016\/j.neuropharm.2021.108771_bib35","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1046\/j.1471-4159.2002.01264.x","article-title":"Up-regulation of the neuronal serotoninergic phenotype in vitro: BDNF and cAMP share Trk B-dependent mechanisms","volume":"83","author":"Rumajogee","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2021.108771_bib36","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.celrep.2018.05.059","article-title":"Aberrant striatal activity in parkinsonism and levodopa-induced dyskinesia","volume":"23","author":"Ryan","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2021.108771_bib37","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mds.22885","article-title":"BDNF levels are not related with levodopa-induced dyskinesias in MPTP monkeys","volume":"25","author":"Samadi","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2021.108771_bib39","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuint.2019.01.011","article-title":"The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice","volume":"124","author":"Sano","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2021.108771_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuropharm.2012.11.010","article-title":"L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells","volume":"67","author":"Stansley","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108771_bib41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/jpet.114.218966","article-title":"Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleus","volume":"351","author":"Stansley","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2021.108771_bib42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001756-199902250-00034","article-title":"Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats","volume":"10","author":"Tanaka","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2021.108771_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.expneurol.2017.07.017","article-title":"BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats","volume":"297","author":"Tronci","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jchemneu.2006.01.007","article-title":"Differential projections of dorsal raphe nucleus neurons to the lateral septum and striatum","volume":"31","author":"Waselus","year":"2006","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.neuropharm.2021.108771_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2021.108771_bib46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1254\/jphs.09019FP","article-title":"Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP","volume":"110","author":"Yabe","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2021.108771_bib47","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neuropharm.2009.05.005","article-title":"Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway","volume":"57","author":"Yamamura","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108771_bib48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.neulet.2009.02.065","article-title":"Effects of zonisamide on neurotransmitter release associated with inositol triphosphate receptors","volume":"454","author":"Yamamura","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108771_bib49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1006\/exnr.1999.7274","article-title":"Lesion-induced increase of BDNF is greater in the striatum of young versus old rat brain","volume":"161","author":"Yurek","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2021.108771_bib50","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1073\/pnas.0711839105","article-title":"Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism","volume":"105","author":"Zhang","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of Americ"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821003269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:14:18Z","timestamp":1758438858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821003269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":51,"alternative-id":["S0028390821003269"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108771","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108771"}}